Publication: Treatment
| dc.contributor.authors | Alibaz-Oner F., Direskeneli H. | |
| dc.date.accessioned | 2022-03-15T02:17:02Z | |
| dc.date.accessioned | 2026-01-10T18:08:36Z | |
| dc.date.available | 2022-03-15T02:17:02Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | Glucocorticoids (GC) are required for remission-induction in patients with Takayasu’s arteritis. Remission is usually achieved with high-dose (1 mg/kg/dayor pulse) regimens. A non-biologic disease modifying agent such as methotrexate, azathioprine or leflunomide is suggested as a first-line approach. In relapsing or refractory patients biologic agents tumor necrosis factor inhibitors or tocilizumab are chosen as second-line treatments. Except in acute ischemic episodes, vascular interventions should be performed in remission phases and under immunosuppressive regimens. © 2021, Springer Nature Switzerland AG. | |
| dc.identifier.doi | 10.1007/978-3-030-67175-4_12 | |
| dc.identifier.issn | 22826505 | |
| dc.identifier.uri | https://hdl.handle.net/11424/248274 | |
| dc.language.iso | eng | |
| dc.publisher | Springer Nature | |
| dc.relation.ispartof | Rare Diseases of the Immune System | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.subject | Biologic agents | |
| dc.subject | Glucocorticoids | |
| dc.subject | Tocilizumab | |
| dc.subject | Tumor necrosis factor inhibitors | |
| dc.title | Treatment | |
| dc.type | bookPart | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 143 | |
| oaire.citation.startPage | 131 | |
| oaire.citation.title | Rare Diseases of the Immune System |